PM 255; Diphenhydramine; Dabylen; PM255; PM-255;Debendrin; Difenhydramine.
Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
Other Sizes |
|
Purity: ≥98%
Diphenhydramine HCl (Dabylen; PM255; PM-255; Debendrin; Difenhydramine), the hydrochloride salt of diphenhydramine, is a 1st-generation histamine H1 receptor antagonist which was approved as an antiemetic for treating various allergic conditions such as rhinitis, urticaria and conjunctivitis.
Targets |
Histamine H1 receptor
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Cell Assay |
Cell Line: PANC-1 cells
Concentration: 0-10 μg/mL Incubation Time: 24 or 48 h Result: Increased the expression of Bad and Bax, and decreased Bcl2 level. Decreased the expression of p-AKT (Thr308), p-AKT (Ser 473), p-mTOR (Ser 2448), p-FoxO1 (Ser 256), p-MDM2 (Ser 166), p-NF-ĸB p65 (Ser 536), and p-GSK-3 (Ser 9). |
||
Animal Protocol |
|
||
References |
Molecular Formula |
C17H22CLNO
|
|
---|---|---|
Molecular Weight |
291.82
|
|
Exact Mass |
291.14
|
|
Elemental Analysis |
C, 69.97; H, 7.60; Cl, 12.15; N, 4.80; O, 5.48
|
|
CAS # |
147-24-0
|
|
Related CAS # |
Diphenhydramine; 58-73-1; Diphenhydramine-d6 hydrochloride; 1189986-72-8; Diphenhydramine-d5 hydrochloride; 1219795-16-0; 88637-37-0 (citrate); 7491-10-3 (salicylate)
|
|
Appearance |
Solid powder
|
|
SMILES |
CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.Cl
|
|
InChi Key |
PCHPORCSPXIHLZ-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C17H21NO.ClH/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;/h3-12,17H,13-14H2,1-2H3;1H
|
|
Chemical Name |
2-benzhydryloxy-N,N-dimethylethanamine;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 130 mg/mL (445.48 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.4268 mL | 17.1338 mL | 34.2677 mL | |
5 mM | 0.6854 mL | 3.4268 mL | 6.8535 mL | |
10 mM | 0.3427 mL | 1.7134 mL | 3.4268 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04175834 | Active Recruiting |
Drug: antihistamine | Multiple Sclerosis Infusion Reaction |
Providence Health & Services | February 5, 2020 | Phase 3 |
NCT02037126 | Active Recruiting |
Drug: Diphenhydramine Drug: Psilocybin |
Cocaine-Related Disorders | University of Alabama at Birmingham |
May 2015 | Phase 2 |
NCT04741139 | Active Recruiting |
Drug: Acetaminophen and Diphenhydramine Only Product |
Immune Thrombocytopenia | Baylor College of Medicine | September 2, 2021 | Phase 1 |
NCT04109885 | Active Recruiting |
Drug: Paracervical injection Drug: prochlorperazine and diphenhydramine. (Standard Treatment) |
Pain Management Emergency Department |
Christian Fromm, MD | September 15, 2020 | Phase 2 |
NCT04805073 | Recruiting | Drug: Promethazine Drug: Placebo |
Pruritus Pregnancy Related |
University of Florida | August 9, 2021 | Phase 4 |